Ramucirumab – A New Treatment Option

The FDA approved the use of the drug ramucirumab (brand name Cyramza®) on April 24, 2015 for patients with metastatic colorectal cancer in combination with FOLFIRI. Ramucirumab with FOLFIRI is now approved for patients whose cancer has progressed during or…  Read More

Another treatment option coming down the pike: TAS-102

Fight Colorectal Cancer stays actively involved in the research process from beginning to end. Part of our role in research is monitoring the progress of new drugs – drugs that may be used in treatment plans of colorectal cancer in…  Read More

Important information to know – from screening to diagnosis for colorectal cancer

Tips From a Member of Our Medical Advisory Board Al B. Benson III, MD, FACP FASCO is Professor of Medicine, Feinberg School of Medicine,  and Associate Director for Clinical Investigations, Robert H. Lurie Comprehensive Cancer Center, Northwestern University One of the nation’s…  Read More

FDA Approves Regorafenib for Metastatic CRC

  The FDA today approved the use of the drug regorafenib (brand name Stivarga) for patients whose metastatic colorectal cancer has progressed despite all currently approved treatment regimens. This is the second new drug approved by the FDA recently after a…  Read More

July 2012 Webinar: Treating Late Stage Colorectal Cancer

Dr. Leonard Saltz of the Memorial Sloan-Kettering Cancer Center explains what treatment options exist for patients with late stage disease. Unfortunately, far too many patients will still hear their doctors say, “We are running out of options.” Fight Colorectal Cancer…  Read More

Highlights from ASCO 2011

While there weren’t new blockbuster announcements for colorectal cancer this year at the American Society for Clinical Oncology’s (ASCO) Annual Meeting, there was plenty of focus on making what we already have work better and on choosing the patients who…  Read More